Showing results (2141-2150 of 2,239) with videos related to
Sort By:
Pageof 224
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.Journal of Extracellular Vesicles|October 4, 2019
Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodulesJia-Tao Zhang, Hao Qin, Fiona Ka Man Cheung, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2021
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC TrialCorinne Faivre-Finn, David Vicente, Takayasu Kurata, et al.Clinical Lung Cancer|October 14, 2021
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable TargetsHai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, et al.Lancet (London, England)|January 28, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyJean-Charles Soria, Daniel S W Tan, Rita Chiari, et al.Clinical Chemistry|March 27, 2004
Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine developmentWai-Yan Choy, Shu-Guang Lin, Paul Kay-Sheung Chan, et al.Lung Cancer (Amsterdam, Netherlands)|November 28, 2019
Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective studyJia-Tao Zhang, Ye Li, Li-Xu Yan, et al.Pageof 224